Several studies have reported that CD19/CD22 dual-targeting CAR T cells exhibit non-superior objective response rates and shorter response durations in ALL or LBCL, potentially due to inadequate CAR T-cell persistence or pharmacokinetics (12, 54, 55). Here, CD19 is linked to acute lymphoblastic leukemia.